Rapport Therapeutics, Inc. Common Stock
$40.45
-$1.50 (-3.58%)
$40.28Day Range$43.00
Key Statistics
Market Cap
$1.94B
Shares Outstanding
48.0M
Primary Exchange
XNAS
Currency
USD
Type
CS
IPO Date
Jun 7, 2024
Round Lot
100
Locale
US
Trading Data
Day Open
$41.89
Day High
$43.00
Day Low
$40.28
Volume
998.1K
VWAP
$40.58
Prev Close
$41.95
Transactions
--
Acc. Volume
--
About Rapport Therapeutics, Inc. Common Stock
Rapport Therapeutics Inc is a clinical-stage biotechnology company dedicated to the discovery and development of small-molecule precision medicines for patients with neurological or psychiatric disorders. The company's portfolio of programs from its RAP technology platform includes RAP-219, an investigational small molecule being developed as a therapy for focal onset seizures, primary generalized tonic-clonic seizures, and bipolar mania. Additionally, it has two discovery-stage nicotinic acetylcholine receptor (nAChR) programs stemming from its RAP technology platform: one being developed for the treatment of chronic pain, and the second, being developed for the treatment of hearing disorders. Geographically, the company operates in the United States.
PHARMACEUTICAL PREPARATIONSSIC 283484 employees99 HIGH STREET, BOSTON, MA, 02110857-321-8020IPO Jun 7, 2024US / STOCKSActiveWebsite
Identifiers
- CIK
- 0002012593
- Composite FIGI
- BBG01FRNQ4P1
- Share Class FIGI
- BBG01FRNQ4V4
- Ticker Root
- RAPP
- SIC Code
- 2834
About Rapport Therapeutics, Inc. Common Stock (RAPP) Stock
Rapport Therapeutics, Inc. Common Stock (RAPP) closed the 2026-09-18 session at $40.45, down 3.58% versus the previous close (-1.50). The stock opened at $41.89 and traded between $40.28 and $43.00 during that session. Session trading volume was 998K shares. The volume-weighted average price (VWAP) is $40.58.
Rapport Therapeutics Inc is a clinical-stage biotechnology company dedicated to the discovery and development of small-molecule precision medicines for patients with neurological or psychiatric disorders. The company's portfolio of programs from its RAP technology platform includes RAP-219, an investigational small molecule being developed as a therapy for focal onset seizures, primary generalized tonic-clonic seizures, and bipolar mania. Additionally, it has two discovery-stage nicotinic acetylcholine receptor (nAChR) programs stemming from its RAP technology platform: one being developed for the treatment of chronic pain, and the second, being developed for the treatment of hearing disorders. Geographically, the company operates in the United States.
Rapport Therapeutics, Inc. Common Stock has a market capitalization of $1.94 billion. The company operates in the PHARMACEUTICAL PREPARATIONS industry classification. RAPP is listed on the XNAS exchange. The company employs approximately 84 people. Rapport Therapeutics, Inc. Common Stock is headquartered in BOSTON, MA. The recorded listing date is 2024-06-07.
On this page you can find market RAPP stock price data, interactive price charts with multiple timeframes (1 day to max history), company financials including income statements, balance sheets, and cash flow statements, technical indicators (SMA 50, SMA 200, EMA 20, MACD, RSI), latest news and sentiment analysis, dividend history, stock splits, short interest data, float information, and related stocks.
Explore more: View today's market movers, use the stock screener, or browse all sectors. See more stocks in the PHARMACEUTICAL PREPARATIONS sector.